IMT504 protects beta cells against apoptosis and maintains beta cell identity, without modifying proliferation
- PMID: 37568265
- PMCID: PMC10421975
- DOI: 10.14814/phy2.15790
IMT504 protects beta cells against apoptosis and maintains beta cell identity, without modifying proliferation
Abstract
We have demonstrated that oligodeoxynucleotide IMT504 promotes significant improvement in the diabetic condition in diverse animal models. Based on these results, here we evaluated whether these effects observed in vivo could be due to direct effects on β-cells. We demonstrate by immunofluorescence that IMT504 enters the cell and locates in cytoplasm where it induces GSK-3β phosphorylation that inactivates this kinase. As GSK-3β tags Pdx1 for proteasomal degradation, by inactivating GSK-3β, IMT504 induces an increase in Pdx1 protein levels, demonstrated by Western blotting. Concomitantly, an increase in Ins2 and Pdx1 gene transcription was observed, with no significant increase in insulin content or secretion. Enhanced Pdx1 is promising since it is a key transcription factor for insulin synthesis and is also described as an essential factor for the maintenance β-cell phenotype and function. Dose-dependent inhibition of H2 O2 -induced apoptosis determined by ELISA as well as decreased expression of Bax was also observed. These results were confirmed in another β-cell line, beta-TC-6 cells, in which a cytokine mix induced apoptosis that was reversed by IMT504. In addition, an inhibitor of IMT504 entrance into cells abrogated the effect IMT504. Based on these results we conclude that the β-cell recovery observed in vivo may include direct effects of IMT504 on β-cells, by maintaining their identity/phenotype and protecting them from oxidative stress and cytokine-induced apoptosis. Thus, this work positions IMT504 as a promising option in the framework of the search of new therapies for type I diabetes treatment.
Keywords: apoptosis; oligodeoxynucleotides; proliferation; transcription factors; β-Cells.
© 2023 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.
Conflict of interest statement
The authors have nothing to disclose.
Figures





Similar articles
-
Proposed mechanisms for oligonucleotide IMT504 induced diabetes reversion in a mouse model of immunodependent diabetes.Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E380-95. doi: 10.1152/ajpendo.00104.2016. Epub 2016 Jun 21. Am J Physiol Endocrinol Metab. 2016. PMID: 27329801
-
Oligonucleotide IMT504 Improves Glucose Metabolism and Controls Immune Cell Mediators in Female Diabetic NOD Mice.Nucleic Acid Ther. 2021 Apr;31(2):155-171. doi: 10.1089/nat.2020.0901. Epub 2020 Dec 21. Nucleic Acid Ther. 2021. PMID: 33347786
-
Oligodeoxynucleotide IMT504 induces a marked recovery in a streptozotocin-induced model of diabetes in rats: correlation with an early increase in the expression of nestin and neurogenin 3 progenitor cell markers.Diabetologia. 2010 Jun;53(6):1184-9. doi: 10.1007/s00125-010-1694-z. Epub 2010 Mar 11. Diabetologia. 2010. PMID: 20221823
-
Oligodeoxynucleotide IMT504: lack of effect on immune parameters during islet regeneration in single dose streptozotocin-induced diabetes.Diabetes Metab Res Rev. 2012 Feb;28(2):156-63. doi: 10.1002/dmrr.1296. Diabetes Metab Res Rev. 2012. PMID: 21922635
-
MicroRNA-26b inhibits cell proliferation and cytokine secretion in human RASF cells via the Wnt/GSK-3β/β-catenin pathway.Diagn Pathol. 2015 Jun 19;10:72. doi: 10.1186/s13000-015-0309-x. Diagn Pathol. 2015. PMID: 26088648 Free PMC article.
References
-
- Babaya, N. , Nakayama, M. , Moriyama, H. , Gianani, R. , Still, T. , Miao, D. , Yu, L. , Hutton, J. C. , & Eisenbarth, G. S. (2006). A new model of insulin‐deficient diabetes: Male NOD mice with a single copy of Ins1 and no Ins2. Diabetologia, 49(6), 1222–1228. - PubMed
-
- Bernardo, A. S. , Hay, C. W. , & Docherty, K. (2008). Pancreatic transcription factors and their role in the birth, life and survival of the pancreatic beta cell. Molecular and Cellular Endocrinology, 294(1–2), 1–9. - PubMed
-
- Bianchi, M. S. , Bianchi, S. , Hernado‐Insua, A. , Martinez, L. M. , Lago, N. , Libertun, C. , Chasseing, N. A. , Montaner, A. D. , & Lux‐Lantos, V. A. (2016). Proposed mechanisms for oligonucleotide IMT504 induced diabetes reversion in a mouse model of immunodependent diabetes. American Journal of Physiology. Endocrinology and Metabolism, 311(2), E380–E395. - PubMed
-
- Bianchi, M. S. , Calvo, V. , Chasseing, N. A. , Lago, N. , Libertun, C. , Montaner, A. D. , & Lux‐Lantos, V. A. (2012). Oligodeoxynucleotide IMT504: Lack of effect on immune parameters during islet regeneration in single dose streptozotocin‐induced diabetes. Diabetes/Metabolism Research and Reviews, 28(2), 156–163. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials